Application of A.I in Neuro-Oncology

Published by Daniel at October 1, 2021

Radiomics is a method that extracts many features from radiographic medical images using data-characterization algorithms and has the potential to uncover disease characteristics that are difficult to be appreciated by the naked eye.

This field in neuro-oncology has been and will remain to be at the forefront of this revolution. A variety of AI techniques applied to conventional and unconventional neuro-oncology MRI data can already delineate infiltrating margins of diffuse gliomas, discriminate pseudo-progression from actual progression, and prognosticate recurrence and survival more reliably than techniques used in daily clinical practice.

These AI-based radionic devices have the potential to stratify patients into more accurate initial diagnostic, therapeutic pathways and facilitate better dynamic treatment monitoring in concordance with this era of personalized medicine.

GE Healthcare's AI-fueled cardiovascular ultrasound nets FDA clearance

The system also semi-automatically recognizes measurements of blood flow and velocity within the body. Furthermore, at the exact moment, it recognizes the transducer angle utilized by the practitioner and tags each image accordingly, which clarifies the technician’s work and makes the following review of the images a more straightforward process. According to the corporation, these features, combined, aim to save about 7 to 10 minutes per scan.

The Ultra Edition package for the company’s line of Vivid ultrasounds includes learning algorithms that can automatically identify the points in a 2D image obtained from an echocardiogram used to estimate the size of the left ventricle, a relevant metric in diagnosing and managing heart failure and disease.

BiWaze Cough System Receives FDA Clearance to Help Clear Secretions

ABM Respiratory Care, a company with facilities in the USA, Singapore, and India, proclaimed that it had received FDA 510(k) authorization to sell its BiWaze Cough System, a device for removing secretions in patients incapable to cough or clear secretions efficiently.

The BiWaze Cough System consists of a touch-screen device attached to a non-invasive suctioning mask. It is a compact alternative to the invasive and more involved process of upper airway suctioning. The system also renders high-frequency oscillations, between 5-20 Hz, to split up thick secretions and promote their removal from the lungs.

The touch-screen device is about the dimension of notebook paper and weighs less than 9 pounds, including the battery. It also connects to a mobile app to customize oscillation and other therapy settings to optimize the system’s requirements of the user. The device itself can store up to twenty distinctive therapy profiles.

According to the organization, the BiWaze Cough System is excellent for patients with spinal cord injuries or neuromuscular deficiencies. In these patients, the suppressed ability to cough results in the inability to clear respiratory tract secretions, which could obstruct the airway and end in pneumonia if aspiration occurs.

Receiving our first FDA 510(k) authorization is a magnificent accomplishment for the organization, said Vinay Joshi, ABM CEO, in a statement. “We can now focus on achieving our corporate plan of combining additional respiratory treatments into our BiWaze platform system and rendering a genuinely novel method to respiratory care.”

References